Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Phase 2 N=29 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Phase 2 N=40 Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response. — 41 percentage of evaluable patients
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=32 Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
Invasive Breast Cancer
Primary: Rate of Achievement of Pathological Complete Response (pCR) — 9 pathology specimens from participants
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 2 N=215 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response Rate — 35; 24 Participants — p=0.019
Phase 2 N=56 A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response Following Principle Investigator Review — 23.2 percentage of participants
Phase 2 N=110 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 18 percentage of participants
Phase 2 N=45 Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) in the Breast — 4; 38; 3 participants
Phase 2 N=123 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response — 23 Participants
Phase 2 N=55 Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Breast Cancer
Primary: Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab — 300; 300 mg
Phase 2 N=43 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Phase 2 N=83 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=43 BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg
Phase 2 N=102 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Breast Cancer
Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR
Phase 2 N=74 Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Breast Cancer
Primary: Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively. — 13; 8; 33; 54 participants
Phase 3 N=564 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Phase 2 N=17 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Phase 2 N=76 Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
HER2 Negative Breast Cancer
Primary: Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery — 18; 10 percentage of surgical patients
Phase 2 N=19 Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Estrogen Receptor Positive · Male Breast Carcinoma · Progesterone Receptor Positive
Primary: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 1 participants
Phase 1 N=52 BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Metastatic or Locally-advanced Unresectable Breast Cancer
Primary: Phase II Dose of BYL719/Alpelisib (Arm A and Arm B) — 250; 250 mg
Phase 2 N=12 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Estrogen Receptor-negative Breast Cancer · Male Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Disease Control Rate (DCR) — 0 participants
Phase 2 N=21 Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants
Phase 2 N=168 Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate (pCR) — 27 participants
Phase 2 N=29 Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…